Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.
Future oncology (London, England). 2024 Apr 29 [Epub ahead of print]
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Marco Maruzzo, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, GenoaItaly., Pathology Unit, Department of Diagnostics & Public Health, University & Hospital Trust of Verona, 37124, VeronaItaly., Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genoa, 16132, GenoaItaly., Candiolo Cancer Institute, FPO-IRCCS, 10060, CandioloItaly., Department of Medicine and Surgery, University of Parma, 43126, ParmaItaly., Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, 56126, PisaItaly., UOC Oncologia Medica, Istituto Fondazione G. Giglio, 90015, CefalùItaly., Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, 42122, Reggio EmiliaItaly., Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, 35128, PaduaItaly., Pathology Unit, IRCCS Istituto Giannina Gaslini, 16147, GenoaItaly., Oncology Unit 1, Istituto Oncologico Veneto IOV-IRCCS, 35128, PaduaItaly., Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona & Verona University & Hospital Trust, Verona, 37134, Italy., Division of Medical Oncology, Ordine Mauriziano Hospital, 10128, TurinItaly., Oncology Unit, Villa Scassi Hospital, 16149, GenoaItaly., Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK., Medical Oncology Unit, Ospedale San Paolo, 17100, SavonaItaly.